Two Sigma Investments LP lifted its position in INmune Bio, Inc. (NASDAQ:INMB - Free Report) by 444.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 66,384 shares of the company's stock after purchasing an additional 54,200 shares during the quarter. Two Sigma Investments LP owned approximately 0.30% of INmune Bio worth $310,000 at the end of the most recent quarter.
A number of other large investors have also recently made changes to their positions in INMB. Wells Fargo & Company MN raised its stake in INmune Bio by 51.0% during the 4th quarter. Wells Fargo & Company MN now owns 6,377 shares of the company's stock valued at $30,000 after acquiring an additional 2,155 shares during the last quarter. Beacon Pointe Advisors LLC purchased a new position in shares of INmune Bio during the 4th quarter worth approximately $48,000. JPMorgan Chase & Co. raised its stake in shares of INmune Bio by 93.0% during the 4th quarter. JPMorgan Chase & Co. now owns 11,335 shares of the company's stock worth $53,000 after buying an additional 5,461 shares in the last quarter. Mariner LLC purchased a new position in shares of INmune Bio during the 4th quarter worth approximately $65,000. Finally, Financial Advocates Investment Management increased its stake in INmune Bio by 14.8% in the 4th quarter. Financial Advocates Investment Management now owns 15,500 shares of the company's stock valued at $72,000 after purchasing an additional 2,000 shares in the last quarter. 12.72% of the stock is owned by institutional investors and hedge funds.
INmune Bio Stock Down 2.8%
NASDAQ INMB traded down $0.22 during mid-day trading on Friday, hitting $7.70. The stock had a trading volume of 593,330 shares, compared to its average volume of 288,359. INmune Bio, Inc. has a 52-week low of $4.32 and a 52-week high of $10.50. The company has a market cap of $176.98 million, a price-to-earnings ratio of -3.53 and a beta of 1.55. The company has a 50 day simple moving average of $7.53 and a 200 day simple moving average of $7.22.
INmune Bio (NASDAQ:INMB - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.43) EPS for the quarter, meeting analysts' consensus estimates of ($0.43). The company had revenue of $0.05 million for the quarter. As a group, equities analysts anticipate that INmune Bio, Inc. will post -2.24 earnings per share for the current fiscal year.
INmune Bio Profile
(
Free Report)
INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
Further Reading
Before you consider INmune Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and INmune Bio wasn't on the list.
While INmune Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
